Literature DB >> 27122854

Plasma High-Sensitivity C-Reactive Protein Level is Associated with Impaired Estimated Glomerular Filtration Rate in Hypertensives.

Hsu-Shien Shu1, Yi-Yun Tai2, Kai-Ting Chang3, Chun-Yuan Chu4, Po-Chao Hsu5, Ho-Ming Su5, Tsung-Hsien Lin5, Wen-Chol Voon5, Wen-Ter Lai5, Sheng-Hsiung Sheu5.   

Abstract

BACKGROUND: Both inflammation and chronic kidney disease (CKD) are related to cardiovascular disease. Whether inflammatory biomarkers are associated with impaired glomerular filtration rate (GFR) is unclear in hypertensives.
METHODS: We recruited hypertension patients from the cardiovascular clinic of a tertiary medical center in Taiwan. GFR was calculated using the 7-item Modification of Diet in Renal Disease (MDRD) study equation and impaired GFR (IGFR) was defined as GFR less than 60 ml/min/1.73 m(2). High-sensitivity C-reactive protein (hsCRP) kits were used for the measurement of the CRP levels.
RESULTS: In our study, 572 consecutive hypertensive patients were enrolled. The range of patient age was 26-91 years (mean 60.5 ± 11.7), and hsCRP and GFR ranged from 0.01 to 9.99 mg/L and 16.6 to 239.6 ml/min//1.73 m(2), respectively. HsCRP levels were correlated with GFR (p = 0.01) and the presence of IGFR (p = 0.009). Multivariate regression analysis showed hsCRP (p = 0.03), age (p < 0.001) and urinary albumin-to-creatinine ratio (UACR) (p = 0.002) are independent factors associated with GFR. Furthermore, hsCRP levels [odds ratio (OR) = 1.16, 95% CI = 1.03-1.31, p = 0.02], age (OR = 1.09, 95% CI = 1.07-1.12, p < 0.001), and UACR (OR = 1.02, 95% CI = 1.01-1.04, p < 0.001) independently predicted the presence of IGFR using binary logistic regression analysis.
CONCLUSIONS: Information obtained from our study showed that hsCRP is associated with IGFR in hypertensives. KEY WORDS: Chronic kidney disease; C-reactive protein; Glomerular filtration rate; Hypertension; Inflammation.

Entities:  

Year:  2015        PMID: 27122854      PMCID: PMC4804873          DOI: 10.6515/acs20140630c

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  27 in total

1.  K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-04       Impact factor: 8.860

2.  Elevated serum levels of C-reactive protein in hemodialysis patients.

Authors:  D Docci; R Bilancioni; A Buscaroli; L Baldrati; C Capponcini; S Mengozzi; F Turci; C Feletti
Journal:  Nephron       Date:  1990       Impact factor: 2.847

3.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

4.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial.

Authors:  Meg J Jardine; Toshiharu Ninomiya; Vlado Perkovic; Alan Cass; Fiona Turnbull; Martin P Gallagher; Sophia Zoungas; Hiddo J Lambers Heerspink; John Chalmers; Alberto Zanchetti
Journal:  J Am Coll Cardiol       Date:  2010-09-14       Impact factor: 24.094

6.  Excerpts from the US Renal Data System 2009 Annual Data Report.

Authors:  Allan J Collins; Robert N Foley; Charles Herzog; Blanche M Chavers; David Gilbertson; Areef Ishani; Bertram L Kasiske; Jiannong Liu; Lih-Wen Mau; Marshall McBean; Anne Murray; Wendy St Peter; Haifeng Guo; Qi Li; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frederick Dalleska; Frank Daniels; Stephan Dunning; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul W Eggers; Lawrence Agodoa
Journal:  Am J Kidney Dis       Date:  2010-01       Impact factor: 8.860

7.  The Impact of Metabolic Syndrome, Homocysteine, and B Vitamins on Carotid Artery Intima-Media Thickness in Hypertensive Patients.

Authors:  Chung-Pin Liu; Yu-Li Lin; Yen-Hung Lin; Kuan-Yin Pao; Vin-Cent Wu; Ta-Chen Su; Chi-Sheng Hung; Churn-Shiouh Gau; Juey-Jen Hwang
Journal:  Acta Cardiol Sin       Date:  2013-01       Impact factor: 2.672

8.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

9.  Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency.

Authors:  Michael G Shlipak; Linda F Fried; Casey Crump; Anthony J Bleyer; Teri A Manolio; Russell P Tracy; Curt D Furberg; Bruce M Psaty
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

Review 10.  Chronic kidney disease: effects on the cardiovascular system.

Authors:  Ernesto L Schiffrin; Mark L Lipman; Johannes F E Mann
Journal:  Circulation       Date:  2007-07-03       Impact factor: 29.690

View more
  1 in total

1.  The Association between Monocyte HDL-C Ratio and SYNTAX Score and SYNTAX Score II in STEMI Patients Treated with Primary PCI.

Authors:  Metin Çağdaş; Süleyman Karakoyun; Mahmut Yesin; İbrahim Rencüzoğulları; Yavuz Karabağ; Mahmut Uluganyan; Mustafa Ozan Gürsoy; İnanç Artaç; Doğan İliş; Eray Atalay; Öznur Sadioğlu Çağdaş
Journal:  Acta Cardiol Sin       Date:  2018-01       Impact factor: 2.672

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.